Businessweek profiles Harry.
“It’s late Tuesday afternoon and, as usual, Harry M. Jansen Kraemer Jr., chairman and chief executive of Baxter International Inc. (BAX), is awhirl. Since he was named chief executive of the medical-products company in 1999, Baxter has become one of the industry’s best and most consistent growth machines, with revenue and operating profit rising by double-digit rates. Its biosciences unit could soon rival Amgen Inc. (AMGN), thanks in part to recent breakthroughs in vaccine technology. And in June, Baxter announced its fifth big acquisition in 16 months, increasing its staff to more than 48,000.”